NASDAQ:APLM Apollomics (APLM) Stock Price, News & Analysis $6.06 +0.24 (+4.04%) Closing price 08/1/2025 03:58 PM EasternExtended Trading$6.06 0.00 (0.00%) As of 08/1/2025 07:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Apollomics Stock (NASDAQ:APLM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Apollomics alerts:Sign Up Key Stats Today's Range$5.75▼$5.8750-Day Range$5.45▼$7.0852-Week Range$4.47▼$35.98Volume2,779 shsAverage Volume64,437 shsMarket Capitalization$6.66 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain. Its also developing uproleselan (APL-106) that is in Phase 3 clinical trial for the treatment of adult patients with relapsed or refractory AML, as well as Phase 2/3 study with uproleselan for the treatment of newly diagnosed older adults with AML; and APL-108, a second-generation E-selective inhibitor, which has completed Phase 1 clinical trials to treat other liquid and solid cancers. The company's pipeline consists of preclinical stage immuno-oncology product candidates, such as APL-501, APL-502, APL-801 and APL-810. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. The company was incorporated in 2015 and is based in Foster City, California. Read More Apollomics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks2nd Percentile Overall ScoreAPLM MarketRank™: Apollomics scored higher than 2% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Apollomics. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioApollomics has a P/B Ratio of 1.35. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.40% of the float of Apollomics has been sold short.Short Interest Ratio / Days to CoverApollomics has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Apollomics has recently increased by 502.17%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldApollomics does not currently pay a dividend.Dividend GrowthApollomics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.40% of the float of Apollomics has been sold short.Short Interest Ratio / Days to CoverApollomics has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Apollomics has recently increased by 502.17%, indicating that investor sentiment is decreasing significantly. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Apollomics this week, compared to 0 articles on an average week.Search Interest1 people have searched for APLM on MarketBeat in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Apollomics insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 19.13% of the stock of Apollomics is held by institutions.Read more about Apollomics' insider trading history. Receive APLM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Apollomics and its competitors with MarketBeat's FREE daily newsletter. Email Address APLM Stock News HeadlinesApollomics, Inc. (APLMW) stock price, news, quote & history - Yahoo FinanceJuly 11, 2025 | nz.finance.yahoo.comHong-Jung Chen - APLM | Apollomics Inc. - Wall Street JournalJuly 8, 2025 | wsj.comIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as October 23rd. | Brownstone Research (Ad)Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business ProgressApril 3, 2025 | globenewswire.comApollomics, LaunXP enter development, commercial agreement for VebreltinibMarch 31, 2025 | markets.businessinsider.comApollomics and LaunXP Announce Development and Commercialization Agreement for VebreltinibMarch 31, 2025 | globenewswire.comUS Stock Futures Rise as Investors Await Key Inflation DataFebruary 28, 2025 | msn.comAPLM stock touches 52-week low at $6.38 amid market challengesFebruary 11, 2025 | msn.comSee More Headlines APLM Stock Analysis - Frequently Asked Questions How have APLM shares performed this year? Apollomics' stock was trading at $9.75 on January 1st, 2025. Since then, APLM stock has decreased by 37.9% and is now trading at $6.0550. When did Apollomics' stock split? Shares of Apollomics reverse split on Monday, November 25th 2024.The 1-100 reverse split was announced on Thursday, November 21st 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, November 22nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. How do I buy shares of Apollomics? Shares of APLM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Apollomics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Apollomics investors own include NVIDIA (NVDA), Cara Therapeutics (CARA), Akebia Therapeutics (AKBA), Avino Silver & Gold Mines (ASM), Canoo (GOEV), MSP Recovery (LIFW) and Tempest Therapeutics (TPST). Company Calendar Today8/01/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:APLM CIK1944885 Webwww.apollomicsinc.com Phone886-2-7713-7952Fax650-288-1674Employees45Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio1.39 Quick Ratio1.39 Sales & Book Value Annual Sales$1.49 million Price / Sales4.47 Cash FlowN/A Price / Cash FlowN/A Book Value$4.48 per share Price / Book1.35Miscellaneous Outstanding Shares1,100,000Free FloatN/AMarket Cap$6.66 million OptionableNot Optionable Beta0.93 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:APLM) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apollomics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apollomics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.